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ABSTRACT
Objective: To estimate the cost-effectiveness of atomoxetine
for children with attention-deﬁcity/hyperactivity disorder
(ADHD) in the United Kingdom compared with current
alternatives.
Methods: An economic model with Markov processes was
developed to estimate the costs and beneﬁts of atomoxetine
versus other current ADHD treatment options. The model
evaluated atomoxetine in ﬁve patient subgroups according to
treatment history and the existence of comorbidities preclud-
ing stimulant medication. The incremental cost per quality-
adjusted life-year (QALY) was calculated for atomoxetine
treatment algorithms compared with comparator algorithms.
The Markov process incorporated 18 health states, represent-
ing a range of outcomes across all treatment options included
in the algorithms. Utility values were derived from a survey of
83 parents of children with ADHD. The effectiveness and
safety aspects of the treatment options were based on a
thorough review of controlled clinical trials and other clinical
literature, and validated by international experts. Costs and
outcomes were estimated using Monte Carlo simulation over
a 1-year duration, with costs estimated from the perspective
of the National Health Service in England and Wales.
Results: For stimulant-naive patients, the incremental cost
per QALY gained for the atomoxetine algorithm compared
with immediate-release methylphenidate hydrochloride
(MPH) was £15,224 (£13,241 compared with extended-
release MPH). In the stimulant-exposed populations, the
incremental cost per QALY for the atomoxetine algorithm
was between £14,169 and £15,878. For patients contraindi-
cated for stimulant therapies, the incremental cost per QALY
was £11,523 and £12,370 for stimulant-naive and stimulant-
exposed populations, respectively.
Conclusion: The economic evaluation showed atomoxetine
is an effective alternative across a range of ADHD popula-
tions and offers value-for-money in the treatment of ADHD.
Keywords: ADHD, atomoxetine, cost-utility analysis, eco-
nomic evaluation, Markov process, methylphenidate, Monte
Carlo simulation.
Introduction
Attention-deﬁcit/hyperactivity disorder (ADHD) is a
neurobiological disorder, the essential feature of
which is a persistent pattern of inattention and/or
hyperactivity–impulsivity at a level that is developmen-
tally inappropriate [1]. Affected children commonly
exhibit disruptive behavior in the classroom, under-
achieve academically, and tend to be discordant in
relations with family members and peers. In the major-
ity of cases, children with ADHD continue to display
behavioral problems and symptoms of the disorder
throughout adolescence and well into adulthood [2,3].
Difﬁculties associated with the disorder may have
long-term negative consequences with respect to
employment prospects, the forming of good relation-
ships, and the risks of substance abuse, crime, and
accidental injury [4–9]. In the United Kingdom, the
estimated prevalence of ADHD among school-aged
children is approximately 5% [10].
Guidance from the National Institute for Health
and Clinical Excellence (2006) suggests that severe
cases may be treated with stimulant medications if
remedial measures alone prove insufﬁcient [10]. By far
the most widely used medication for ADHD is meth-
ylphenidate hydrochloride (MPH). Available as either
an immediate-release (IR) or an extended-release (XR)
formulation, this drug has been prescribed in more
than 90% of severe cases diagnosed in the United
Kingdom [11]. Dexamphetamine sulfate, another
stimulant, available in the United Kingdom as an IR
formulation (IR-DEX), is prescribed far less frequently,
principally as a second-line therapy in the small
number cases that are refractory to MPH.
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Atomoxetine is an alternative to stimulants in the
treatment of ADHD with once-a-day oral dosing.
There is consistent evidence that atomoxetine is supe-
rior to placebo [12], although existing evidence does
not allow for clear differentiation between atomoxet-
ine and other treatments for ADHD on the grounds of
clinical effectiveness in terms of standard measures of
ADHD symptom control [13]. However, a placebo-
controlled trial has been conducted to test morning
and late-afternoon/evening ADHD symptom relief
using a new, recently validated, parent-reported in-
strument (the Daily Parent Ratings of Evening and
Morning Behavior, Revised [14]). Results suggest that,
among those patients who respond to atomoxetine, a
single dose each morning provides a lasting effect
through to the following morning, provided that the
medication is taken on a regular daily basis [15]. In
contrast, the duration of efﬁcacy of MPH may be more
limited. A single dose of XR-MPH, or three repeated
doses of IR-MPH, will provide approximately
12 hours of therapeutic coverage [16–18]. Conse-
quently, based on their pharmacokinetic and phar-
macodynamic characteristics and using usual dose
regimens, it is unlikely that these drugs would provide
therapeutic coverage through the night or at the time
of waking.
The objective of the present study was to estimate
the cost-effectiveness of using atomoxetine as a new
treatment option for children with ADHD in the
United Kingdom, to determine whether the extra ben-
eﬁts justify the extra cost of atomoxetine. The study
was designed to stratify the comparisons by patient
subgroups, taking into consideration the medication
alternatives available to them, depending on prior
treatment history and whether use of stimulants is
contraindicated by coexisting conditions. The eco-
nomic model was developed to compare the costs and
beneﬁts of treatment algorithms that include atomox-
etine with current treatment algorithms for the man-
agement of ADHD. Results of the model are presented
as the incremental cost per quality-adjusted life-year
(QALY) for atomoxetine relative to current therapy
for each patient population. A comparison of the
costs and health outcomes predicted by the model
is intended to aid decision-makers in determining
whether to publicly fund atomoxetine therapy.
Methods
Patients and Populations
In recognition that 1) children with ADHD are fre-
quently codiagnosed with one or more comorbidities
[19], some of which are contraindicated for medica-
tion with stimulants [20], and 2) a patient’s stimulant
history is a determining factor in clinical outcomes
[21,22], patients in the evaluation are segregated,
according to their treatment history and contraindica-
tion status, into ﬁve mutually exclusive patient groups:
1. Stimulant-naive patients are patients with no
history of pharmacotherapy use and no contrain-
dications to stimulants.
2. Stimulant-failed patients are individuals who have
been previously (prior to entry into the model)
medicated with methylphenidate but have failed
this therapy because of lack of efﬁcacy or intoler-
able side effects.
3. Stimulant-averse patients are those who have
experience of stimulant medication and have
responded successfully but would like to stop their
medication if a nonstimulant medication was
available.
4. Stimulant-contraindicated patients (naïve) are
patients who have no history of pharmacotherapy
use but are precluded from using stimulant thera-
pies because of a pre-existing contraindicated
condition(s), including severe depression, marked
anxiety, tics, a family history or diagnosis of
Tourette’s syndrome, known drug dependence or
a history of drug dependence or alcoholism [20].
5. Stimulant-contraindicated patients (exposed) are
those who have been previously treated with a
stimulant therapy but are now precluded from
using stimulant therapies because of one or more
conditions—including severe depression, marked
anxiety, tics, a family history or diagnosis of
Tourette’s syndrome, known drug dependence
or a history of drug dependence or alcoholism
—potentially developed while receiving stimulant
therapy [20].
Patients who are currently successfully being treated
with methylphenidate, and who are satisﬁed with this
treatment, are excluded from the analysis because it is
assumed that these patients are unlikely to switch
medication.
Treatments and Comparators
The primary outcome of the analysis is to estimate the
cost-effectiveness of atomoxetine based on the treat-
ment algorithms available to, and commonly used by,
each of the ﬁve patient populations. Accordingly, the
model considers the four treatment options available
in the United Kingdom, namely atomoxetine, MPH
(XR and IR), dexamphetamine, and “no medication.”
Overall, we consider treatment strategy in the follow-
ing order: atomoxetine, MPH (either XR or IR),
dexamphetamine, and no treatment. Atomoxetine is
considered as the ﬁrst choice to allow the model fully
to capture the potential effects of introducing atomox-
etine to the United Kingdom. With respect to MPH,
two formulations of MPH (XR and IR) are assumed
similar enough to each other that if one formulation
does not work for a patient, the other formulation
Atomoxetine: A Modeled Economic Evaluation 377
will not be considered an alternative therapy. When
contraindications and past stimulant failure are con-
sidered for each patient group, unique treatment strat-
egies emerge for each group. Figure 1 summarizes the
treatment algorithms, with and without atomoxetine,
for each of the ﬁve patient populations.
Model Structure
An economic model, constructed using DATA Pro soft-
ware [23], was developed to calculate and compare the
costs and beneﬁts of the various treatment algorithms,
with and without atomoxetine, available to each
patient population, using Monte Carlo simulations of
a Markov process. The economic evaluation uses a
cost-utility analysis to calculate the incremental cost
per QALY gained by atomoxetine compared with the
prevailing therapeutic options available in the United
Kingdom.
Themodel uses aMonte Carlo simulationwhereby a
single patient is followed through the Markov process
in monthly cycles over a period of 1 year. It was deemed
inappropriate to extend the model beyond the time
frame covered by the available clinical data. Instead, it
is implicitly assumed that there is no difference in health
beneﬁts between the medications in the longer term.
Costs and outcomes are accumulated as the patient
advances through the cycles and 20,000 simulations are
performed for each patient population to establish the
mean costs and outcomes across all possible transitions
through the Markov process (Fig. 2). These results are
then used to calculate incremental cost-effectiveness
ratios for each comparison in the different patient
populations. Given that the model duration is within
1 year, costs and effects were not discounted. The
Markov process used a half-cycle correction, which
meant that patients were attributed their initial health
state utility values half way through the ﬁrst cycle.
Upon entering the Markov process, patients are
distributed into one of four health states per treatment
they receive, their response to that treatment, and
occurrence of any adverse events associated with that
treatment. Upon failure of therapy, patients move
through to the next treatment option speciﬁed by that
algorithm.
The 18 health states in which patients can reside
cover all possible combinations of treatment-events
that patients may experience. Patients remain within
their resident health state until one of the following
events occur.
1. The patient discontinues medication because of
lack of efﬁcacy—applicable only to patients on an
active treatment and in a nonresponder health
state. The model assumes a maximum of two con-
secutive nonresponse cycles. A third nonresponse
cycle results in automatic discontinuation because
Population 1: 
Stimulant-naïve patients 
Evaluation (a): IR-MPH comparison 
Population 1: 
Stimulant-naïve patients 
Evaluation (b): XR-MPH comparison 
Population 2: 
Stimulant-failed patients 
Population 4: 
Stimulant-contraindicated patients (naïve)
Population 3: Stimulant-averse patients 
Evaluation (a): IR-MPH comparison  
Population 3: Stimulant-averse patients 
Evaluation (b): XR-MPH comparison  
Same as Population 1; Evaluation (a) Same as population 1; Evaluation (b) 
Population 5: Stimulant-contraindicated 
patients (exposed) 
Same as Population 4 
Figure 1 Treatment algorithms compared in
the economic model, by patient population. For
deﬁnitions of the patient populations, see
Methods. aIn populations 1 and 3, two evalua-
tions were undertaken. Evaluation (a) in these
populations refers to an analysis where IR-MPH
is considered the stimulant therapy of choice.
Evaluation (b) in these populations refers to an
analysis where XR-MPH is considered the
stimulant therapy of choice.ATX, atomoxetine;
IR-DEX, immediate-release dexamphetamine
sulfate; IR-MPH, immediate-release meth-
ylphenidate; XR-MPH, extended-release meth-
ylphenidate; Rx, medication.
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of lack of efﬁcacy. After discontinuing one medi-
cation, the patient will switch immediately to the
next alternative in the treatment algorithm to
begin the next Markov cycle.
2. The patient discontinues medication because of a
medication-related adverse event and progresses
to the next line of therapy according to the treat-
ment algorithm.
3. An adverse event resolves.
4. The patient discontinues medication for any other
reason—applicable equally to all patients on
active treatment. These patients are assumed to
stop therapy altogether.
5. The patient relapses—applicable only to those
patients in a responder health state. A patient who
relapses becomes a nonresponder in the following
Markov cycle.
6. The patient experiences a delayed response to
medication (this possibility is examined only in a
sensitivity analysis)—applicable only to those
patients on an active treatment and in a nonre-
sponder health state. A patient who experiences a
delayed response becomes a responder in the fol-
lowing Markov cycle.
Although the structure of the Markov process is
identical for each of the initial treatment options in the
model, the distribution of patients across the health
states and transition between health states depend on
the treatment that the patient is receiving at any par-
ticular time. Parameters are dependent on health state
and treatment line (e.g., the probability of response
with atomoxetine is different in ﬁrst- and second-line
settings). Patients who discontinue medication alto-
gether will move to one of the two “no medication”
health states and remain in this health state for the
duration of the model.
The model structure allows estimation of the
expected costs and health outcomes for each treatment
algorithm. Results are presented as the incremental
cost per QALY gained of the introduction of atomox-
etine for each of the patient populations.
Model Variables
Costs. Costs are estimated from the perspective of the
National Health Service in England and Wales, and
only study drug costs are included. This assumes that
all nondrug health-care costs and indirect costs are
equivalent between the treatment groups being com-
pared. Such an assumption may be considered biased
against the active therapies that have the potential to
reduce symptoms and, consequently, a patient’s
Treatment:    ATX
Treatment:    ATX
Treatment:    ATX
Treatment:    ATX
Response:    Yes
Response:    Yes
Side-effects: No
Side-effects: 
Response:    No
Side-effects: No
Response:    No
Side-effects: 
Treatment:    IR-MPH
Response:    Yes
Side-effects: No
Treatment:    IR-MPH
Response:    Yes
Side-effects: Yes
Treatment:    IR-MPH
Response:    No
Side-effects: No
Treatment:    IR-MPH
Response:    No
Side-effects: Yes
Treatment:    XR-MPH
Response:    Yes
Side-effects: No
Treatment:    XR-MPH
Response:    Yes
Side-effects:
Treatment:    XR-MPH
Response:    No
Side-effects:
Treatment:    XR-MPH
Response:    No
Side-effects:
Treatment:     No tx.
Response:     Yes
Side-effects:  N/A
Treatment:     No tx.
Response:     No
Side-effects:  N/A
a
Response: 
Side-effects:
Treatment:
Response:
Side-effects:
Treatment:
Response:
Side-effects:
Treatment:
Response:
Side-effects:
b
b
aaa
Treatment:    
Yes
Yes
No
Yes
Yes
DEX
Yes
DEX
Yes
Yes
No
DEX
No
No
DEX
No
Yes
Figure 2 Structure of the Markov process used to estimate costs and outcomes of individual treatment options. aRepresents transitions between health
states where the patient is discontinuing pharmacotherapy. bRepresents transitions between health states where the patient is starting a new pharma-
cotherapy (after discontinuing a previous pharmacotherapy). ATX, atomoxetine; DEX, immediate-release dexamphetamine sulfate; IR-MPH, immediate-
release methylphenidate; N/A, not applicable; tx, treatment; XR-MPH, extended-release methylphenidate.
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reliance on health-care professionals. Furthermore,
the cost of drugs associated with the treatment of
medication-related side effects is not considered.
Because of the persistence of insomnia, patients treated
with stimulants (IR-MPH, XR-MPH, IR-DEX) are
more likely than patients treated with atomoxetine to
require medication for side effects, indicating that
the exclusion of these costs may be biased against
atomoxetine.
Cost variables used in the Markov process and their
respective data sources are summarized in Table 1. The
cost for atomoxetine, based on most patients’ need for
only a single capsule a day, independent of capsule
strength, is £1.95. In the evaluation, however, the base
case uses a more conservative daily cost of £2.15,
assuming 10%of patients take two capsules to reach an
optimal dose. Calculation of the daily cost of stimulant
medications is based on the estimated average daily
dose taken by patients [24] and the relative use of
available pack sizes for each medication according to
current market research. Unit costs of stimulant medi-
cationwere derived from the UK edition of theMonthly
Index of Medical Specialities [25]. Patients in the model
receive 30 days of medication per monthly cycle.
Health State Utility Values
Health state utility values for 14 of the 18 possible
health states included in the economic model were
based on a utility valuation survey of 83 parents of
children with ADHD in the United Kingdom using
standard gamble methodology [26]. The health-state
description consisted of four domains: 1) descriptors
referring to behavior during different time periods
throughout the day; 2) information concerning the
child’s overall social well-being; 3) attributes regarding
medication regimen (e.g., frequency of administration);
and 4) medication-related adverse events. Parents were
chosen as the most suitable patient proxy respondents
on the basis thatmanyADHDchildrenwithin the target
population would be too young to provide reliable
responses. The survey did not include utility estimates
for four health states associated with IR-DEX therapy.
In each case, however, parity with IR-MPH has been
assumed, based on clinical expert opinion.
The health state corresponding to the atomoxetine
“responder without side effects” had the highest
utility value (0.959). Health states corresponding to
“responder without side effects” for XR-MPH and
IR-MPH had utility values of 0.930 and 0.913, respec-
tively. For each of the “no medication” health states,
utility values of 0.880 were obtained from the “child’s
own health state” as given by a subgroup of 23 parents
whose children were not currently receiving medica-
tion. When compared with the values obtained for the
theoretical “no-medication” health states, the utility
value obtained for the unmedicated child’s own state
was found to be lower than the range of the theoretical
states (0.899–0.950), and very close to the “nonre-
sponder without side effects” values for the three medi-
cations (0.878, 0.847, 0.861) derived from the same
sample of 23 parents. It was deemed more appropriate
to apply the “child’s own health state” utility value
given by the parents of unmedicated children to all
unmedicated patients in the model. It is worth noting
that the “child’s own health state” utility value given
by the remaining 60 parents whose children were
medicated was 0.917. This value is similar to the
values given for theoretical IR-MPH and XR-MPH
responder health states (0.913, 0.904, 0.930, 0.912),
thus providing reassurance that the “child’s own
health state” utility values are reliable. In the sensitiv-
ity analysis, a value of 0.934 (upper conﬁdence limit)
for nonmedication responders was tested. Table 2
presents the utility scores utilized in the economic
model.
The utility values generated were applied to the
appropriate health states within the model, regardless
of contraindication status to stimulants of the patient
population or the line of therapy within any treatment
algorithm.
Transition Probabilities
Transition probabilities used to populate the Markov
process and respective data sources are presented in
Tables 3 and 4.
Probabilities that did not vary by patient popula-
tion (Table 3), including probabilites of medication-
related adverse events and discontinuations from
Table 1 Medication costs in the economic model
Atomoxetine cost IR-MPH cost XR-MPH cost IR-DEX cost
Average daily dose 1.1 capsules 25.46 mg* 32.75 mg* 13.11 mg*
Daily cost of medication £2.15† £0.47‡ £1.34‡ £0.18‡
Days on medication per Markov cycle 30 30 30 30
Cost of medication per Markov cycle £64.35 £14.19 £40.05 £5.40
*Primary care data [24].
†Daily cost of atomoxetine is independent of average daily dose. Cost is based on a cost per capsule, independent of capsule strength [25] and accommodates 10% of patients
requiring two rather than one capsule per day.
‡Daily costs of stimulants based on current costs [25] applied to the average daily dose, weighted by the relative days of therapy of each pack size for each medication. Figures
are rounded to nearest £0.01.
IR-DEX, immediate-release dexamphetamine sulfate; IR-MPH, immediate-release methylphenidate; XR-MPH, extended-release methylphenidate.
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treatment, were derived from placebo-controlled clini-
cal trials for atomoxetine [27–34] and an indirect
meta-analysis of safety data from randomized placebo-
controlled and active comparator studies of atomox-
etine and methylphenidate [35].
Medication-related adverse events were deﬁned as
any adverse event 1) found to be signiﬁcant for ato-
moxetine in a pooled analysis of safety data from six
pivotal randomized placebo-controlled trials [27–33];
2) found to be signiﬁcant for IR-MPH in a published
Table 2 Utility values derived from the utility valuation survey
Health state N Mean utility value SD 95% CI
Medication with atomoxetine; responder without side effects 83 0.959 0.077 0.942–0.976
Medication with atomoxetine; responder with side effects 83 0.937 0.096 0.916–0.958
Medication with atomoxetine; nonresponder without side effects 83 0.902 0.133 0.873–0.931
Medication with atomoxetine; nonresponder with side effects 83 0.886 0.148 0.854–0.918
Medication with IR-MPH; responder without side effects 83 0.913 0.128 0.885–0.941
Medication with IR-MPH; responder with side effects 83 0.904 0.137 0.875–0.933
Medication with IR-MPH; nonresponder without side effects 83 0.889 0.154 0.856–0.922
Medication with IR-MPH; nonresponder with side effects 83 0.875 0.164 0.840–0.910
Medication with XR-MPH; responder without side effects 83 0.930 0.107 0.907–0.953
Medication with XR-MPH; responder with side effects 83 0.912 0.124 0.885–0.939
Medication with XR-MPH; nonresponder without side effects 83 0.898 0.130 0.870–0.926
Medication with XR-MPH; nonresponder with side effects 83 0.884 0.143 0.853–0.915
No medication; responder* 23 0.880 0.133 0.826–0.934
No medication; nonresponder* 23 0.880 0.133 0.826–0.934
*Utility values for “child’s own health states.”
CI, conﬁdence interval; IR-MPH, immediate-release methylphenidate; SD, standard deviation; XR-MPH, extended-release methylphenidate.
Table 3 Transition probabilities used in the Markov process that do not vary by patient population
Probability by treatment option
Atomoxetine IR-MPH XR-MPH IR-DEX No medication
Probability of one or more medication-related adverse events* 0.129 0.129 0.129 0.129 0.000
Probability that a medication-related adverse event is insomnia† 0.000 0.460 0.460 0.460 NA
Probability that a medication-related adverse event, which is not insomnia,
will persist from one Markov cycle to the next‡
First four cycles 0.473 0.473 0.473 0.473 NA
Cycles thereafter 1.000 1.000 1.000 1.000 NA
Probability that insomnia will persist from one Markov cycle to the next§
First four cycles NA 0.953 0.953 0.953 NA
Cycles thereafter NA 1.000 1.000 1.000 NA
Probability that a nonresponder discontinues because of lack of efﬁcacy during a
Markov cycle¶
0.0989 0.0989 0.0989 0.0989 NA
Probability that a patient discontinues because of medication-related adverse event
during a Markov cycle**
0.1209 0.1209 0.1209 0.1209 NA
Probability that a patient discontinues for reasons other than lack of
efﬁcacy or a medication-related adverse event during a Markov cycle¶
First four cycles 0.384 0.384 0.384 0.384 NA
Cycles thereafter 0.000 0.000 0.000 0.000 NA
*Probabilities based on post-hoc analyses of safety data pooled from six randomized placebo-controlled trials of atomoxetine versus placebo [27–33]. Assumption of parity
between active treatments based on similar post hoc analyses of data from a limited open-label direct comparator study [40], supported by data from a double-blind randomized
trial of atomoxetine and XR-MPH [42] where the proportions of patients experiencing one or more adverse event of any nature were not signiﬁcantly different between the
active treatments.Values are net of the placebo rate, meaning that the “no medication” probability is zero, by deﬁnition.
†The probability based on the relative risk (0.428) of insomnia (atomoxetine vs. IR-MPH), estimated in an indirect meta-analysis of safety data [35], applied to the risk of insomnia
for atomoxetine (4.7%) derived from pooled analysis of safety data from six pivotal randomized placebo-controlled trials of atomoxetine [5,27], giving a rate of insomnia for
IR-MPH of 4.7/0.428 = 11%. The model assumes that insomnia is experienced only as a result of taking medication. Therefore, the probability for placebo is not applicable
(i.e., zero) and the probabilities for active treatments are net of the placebo rate (i.e., subtract 5.1%).As a consequence, the model assumes that patients on atomoxetine have
no risk of medication-related insomnia. Patients on IR-MPH who experience insomnia will come only from the population who experience one or more adverse events as derived
above.Therefore for “if adverse event, probability that insomnia included” = (11.0–5.1)/12.9 = 46%. Parity is assumed between the stimulant treatments [16,18,22,45,46].
‡Probabilities based on temporal course of treatment-emergent adverse events where weekly reports from patients treated with atomoxetine over 52 weeks imply that, for most
patients, medication-related adverse events mainly occur early in the treatment and are likely to resolve within approximately 16 weeks.The probability of 0.473 (0.051/4) for the
ﬁrst four cycles with adverse event reﬂects a nominal 5% of patients in whom adverse events (that are not insomnia) persist over this duration of the Markov process.The duration
of persistence of adverse events (that are not insomnia) is assumed to be similar for each medication.
§Probabilities based on a survey of six consultant child and adolescent psychiatrists [38]. Responses suggested that 82.5% of cases of stimulant-related insomnia would persist for
more than 16 weeks.The model assumes that patients with stimulant-related insomnia that persists beyond four cycles will continue to have insomnia as long as they remain on
treatment.The probabilities of 0.953 (0.8241/4) for the ﬁrst four cycles of the Markov process and 1.000 for cycles thereafter reﬂect this.
¶Probabilities based on discontinuation rates, regardless of treatment, from data pooled from seven randomized placebo-controlled trials of atomoxetine [27–34], adjusted for
differences between trials with respect to duration of follow-up. Discontinuations due to lack of efﬁcacy were assumed to occur in only the nonresponder population. In each
case, parity is assumed between the active treatments.
**Probabilities based on discontinuation rates due to adverse events from data pooled from six pivotal randomized placebo-controlled trials of atomoxetine [27–33], adjusted
for differences between trials with respect to duration of follow-up. Discontinuations due to adverse events were assumed to occur only in the population experiencing one or
more medication-related adverse events and therefore were net of the placebo rate. In each case, parity is assumed between the active treatments.
IR-DEX, immediate-release dexamphetamine sulfate; IR-MPH, immediate-release methylphenidate; NA, not applicable; XR-MPH, extended-release methylphenidate.
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quantitative meta-analysis of safety data from ran-
domized controlled trials [36]; or 3) listed as very
common (frequency 10%) for Ritalin® and/or
Concerta® XL in Summary Product Characteristics
[20]. Medication-related adverse events comprised
appetite loss, stomachache, vomiting, somnolence,
irritability, dizziness, fatigue, insomnia, headache,
and nervousness.
Assumptions regarding the persistence of
medication-related adverse events are based on long-
term treatment data for atomoxetine [37], where
weekly reports of adverse events, either as a ﬁrst or a
repeat occurrence, fell off with time to fairly constant
low levels which, in many cases, are considered to be
close to the baseline reporting of such adverse events.
These data imply that for most patients, medication-
related side effects mainly occur early on in the treat-
ment and are likely to resolve within approximately
16 weeks.
Data concerning time to resolution for
methylphenidate-related adverse events are not
available. Because adverse events associated with
methylphenidate are mostly considered mild and
transient, the model assumes that, with one excep-
tion, the time to resolution for methylphenidate-
related adverse events is the same as for atomoxetine.
The exception to this is stimulant-associated insom-
nia, which can persist in a proportion of cases. The
probability that medication-related insomnia persists
in methylphenidate-treated patients is based on
responses collected in a survey of consultant child
and adolescent psychiatrists, all highly experienced in
treating children with ADHD [38].
Probabilities of response and relapse vary by patient
population (Table 4). The evidence base for these vari-
ables in each of the populations is described below.
Stimulant-naive patients. Probabilities of treatment
response in patients naive to stimulants are derived
from responder rates estimated in a meta-regression
analysis [39] of patient-level data from ﬁve random-
ized active comparator trials of atomoxetine and meth-
ylphenidate [27,28,40–43].
Stimulant-failed patients. The probability of response
to IR-DEX in stimulant-exposed patients who have
failed on MPH is derived from a crossover study of
IR-DEX and IR-MPH in which a subgroup who failed
to respond to IR-MPH were found to respond to
IR-DEX [22]. The deﬁnition of response used in this
crossover study was not the same as that used in this
model. Nevertheless, the responder rate for IR-MPH in
the ﬁrst phase of the crossover study was comparable to
the responder rate for MPH in naive patients obtained
in the aforementioned meta-regression analysis [39]. It
was therefore considered reasonable to take the rate of
response to IR-DEX in the subgroup that did not
respond to MPH from this trial and use it in the model.
Data from a randomized trial of atomoxetine and
MPH [43] have similarly suggested that a subgroup of
Table 4 Transition probabilities used in the Markov process that vary by patient population
Probability by treatment option
Patient population Atomoxetine IR-MPH XR-MPH IR-DEX No medication
Probability of response
to treatment
1. Stimulant-naive* 0.7051 0.7727 0.7727 NA NA
2. Stimulant-exposed (failure)† 0.6674 NA NA 0.6674 0.3983
3. Stimulant-exposed (averse)‡ 0.6217 0.7003 0.7003 0.6217 0.3983
4. Contraindicated, stimulant-naive§ 0.6667 NA NA NA 0.4231
5. Contraindicated, stimulant-exposed§ 0.5273 NA NA NA 0.3478
Probability of relapse
per 30-day period¶
1. Stimulant-naive 0.0206 0.0206 0.0206 NA NA
2. Stimulant-exposed (failure) 0.0257 NA NA 0.257 0.0447
3. Stimulant-exposed (averse) 0.0257 0.0257 0.0257 0.0257 0.3983
4. Contraindicated, stimulant-naive 0.0206 NA NA NA 0.0387
5. Contraindicated, stimulant-exposed 0.0257 NA NA NA 0.0447
*Probabilities of response in stimulant-naive patients in whom stimulants are not contraindicated are based on a meta-regression analysis [39] of response data from randomized
active comparator trials of atomoxetine and methylphenidate (MPH) [27,28,40–43]. Assumption of parity between stimulants is based on head-to-head trials of IR-MPH and
XR-MPH [16,18].
†Probabilities of response in MPH-exposed (failed) patients in whom stimulants are not contraindicated are based on responder rates in a crossover trial of IR-MPH and IR-DEX
[22]. Parity is assumed for atomoxetine and IR-DEX in patients who have failed to respond to MPH.The probability of response for “no medication” is derived from factoring
down the rate of IR-DEX responders in IR-MPH-failed patients by applying the relative risk of response for placebo versus atomoxetine for stimulant-naïve patients derived in
the meta-regression analysis.
‡Probabilities of response in MPH-exposed (nonfailure) patients in whom stimulants are not contraindicated are based on a meta-regression analysis [39] of response data from
randomized active comparator trials of atomoxetine and MPH [27,28,40–43].Assumption of parity between stimulants is based on head-to-head trials of IR-MPH and XR-MPH
and IR-MPH and IR-DEX [16,18,22,46]. Parity is assumed for atomoxetine and IR-DEX in patients who have been exposed to MPH.The probability of response for“no medication”
is derived from factoring down the rate of IR-DEX responders in IR-MPH-failed patients by applying the relative risk of response for placebo versus atomoxetine for
stimulant-naïve patients derived in the meta-regression analysis.
§Probabilities of response in stimulant-naïve and stimulant-exposed patients in whom stimulants are contraindicated are based on responder rates from a randomized
placebo-controlled trial of atomoxetine in patients with tics or Tourette’s syndrome [34].
¶Probability of relapse = 1 - [(1 - C)(1/E)], where C = the proportion of patients relapsing and E = approximate total number of follow-up days, derived from a relapse prevention
study [44,45], divided by the approximate number of days per Markov cycle. Parity is assumed between active medications.
IR-DEX, immediate-release dexamphetamine sulfate; IR-MPH, immediate-release methylphenidate; Stimulant-exposed, patients with attention-deﬁcit/hyperactivity disorder
(ADHD) who have previously tried and failed on MPH because of lack of response; Stimulant-naive,ADHD patients who have never been exposed to MPH, dexamphetamine,
or any other stimulant medication; XR-MPH, extended-release methylphenidate; Failure/nonfailure, whether stimulant-exposed patients failed MPH or not.
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patients who fail to achieve a response with MPH
achieve a response with atomoxetine. In the absence of
evidence using comparable deﬁnitions of response,
parity of probability of response is assumed between
atomoxetine and IR-DEX in patients who have failed
to respond to IR-MPH or XR-MPH.
For those patients for whom “no medication” is the
only remaining option in their medication algorithm,
the probability of response is derived from factoring
down the rate of IR-DEX responders in patients who
failed to respond to IR-MPH [22] by applying the
relative risk of response for placebo versus atomoxet-
ine for naive patients derived in the meta-regression
analysis [39].
Stimulant-averse patients. The probability of response
in the stimulant-averse population is derived from
responder rates estimated for stimulant-exposed
patients in the meta-regression analysis [39] in which
all patients with history of stimulant use prior to
enrollment in the clinical trials had responded to their
medication. Therefore, these data constitute an appro-
priate evidence base for this patient population in the
model who also have a history of stimulant use.
Stimulant contraindicated patients. Probabilities of
treatment response in patients contraindicated for
stimulants were derived from responder rates in
stimulant-exposed and stimulant-naïve patients in a
randomized placebo-controlled trial of atomoxetine
conducted exclusively in an ADHD patient group who
had been codiagnosed with tic disorder or Tourette’s
syndrome [34]. The limitation of this, of course, is that
patients with tics or Tourette’s syndrome constitute a
subgroup of, rather than being representative of, the
overall stimulant-contraindicated population. Never-
theless, in the absence of data from a more appropriate
patient group, this is the best estimate available.
Probabilities of relapse were based on data for
stimulant-naive and stimulant-exposed patients in a
placebo-controlled relapse prevention trial of atomox-
etine responders [44,45]. In the absence of compara-
tive data, an assumption of parity is made between
relapse rates for all active treatment and also between
patients who are contraindicated for stimulants and
those who are not.
For all transition probability variables, where appli-
cable, the assumptions of parity between IR-MPH and
XR-MPH and between IR-MPH and IR-DEX are
based on data published from head-to-head trials of
treatments [16,18,22,46,47].
Sensitivity analysis. Extensive sensitivity analyses were
carried out on all cost, utility, and transition probability
variables. Full details of the sensitivity analysis are
available by contacting the authors. The results of key
ﬁndings are presented in the Results section.
Results
The results of the economic model are summarized In
Table 5. Overall, the results of the model suggest that
improved health outcomes, translated into increased
QALYs, are possible with a treatment algorithm in-
cluding atomoxetine compared with an algorithm
without atomoxetine. This result was consistent across
the ﬁve populations evaluated.
For the stimulant-naive population (population 1),
inclusion of atomoxetine in the treatment algorithm
was associated with additional costs of £408.34
(compared with the IR-MPH algorithm; Evaluation A)
or £265.71 (compared with the XR-MPH algorithm;
Evaluation B) per patient. The additional cost of the
atomoxetine algorithm in stimulant-failed patients
(population 2) was £448.78. In the stimulant-averse
patients (population 3), it was £373.79 (compared
with the IR-MPH algorithm; Evaluation A) or £256.13
(compared with the XR-MPH algorithm; Evaluation
B). In the patient populations with contraindications
to stimulant therapy, the incremental cost of the ato-
moxetine algorithm was £480.94 in those naïve to
stimulant therapies (population 4) and £395.98 in
those with a history of stimulant use (population 5).
Patients in the atomoxetine treatment group expe-
rienced greater time with response and greater time on
medication (results not shown). This, together with the
higher utility value associated with a response to ato-
moxetine relative to the other therapies included in the
model, translated into QALY gains for patients in the
atomoxetine algorithm. The atomoxetine algorithm
was associated with QALY gains of 0.027 (compared
with the IR-MPH algorithm; Evaluation A) or 0.020
(compared with the XR-MPH algorithm; Evaluation
B) in the stimulant-naive population. In the stimulant-
failed population, the atomoxetine algorithm was
associated with 0.030 additional QALYs. In the
stimulant-averse patient population, the QALY gains
were 0.024 and 0.018 for the IR-MPH (Evaluation A)
and XR-MPH (Evaluation B) comparisons, respec-
tively. For patients with contraindications, the QALY
gains in the atomoxetine algorithm were 0.042 for
stimulant-naïve patients and 0.032 for stimulant-
exposed patients compared with no medication.
The incremental cost per QALY gained with
atomoxetine varied from £11,523 in contraindicated
stimulant-naïve patients (population 4) to £15,878
when compared with the IR-MPH algorithm in
stimulant-averse patients (population 3; Evaluation
A). This is an intuitive result because atomoxetine is
most cost-effective in the patient group in which there
are no pharmacotherapy alternatives currently avail-
able, and least cost-effective in the patient group who
are responding to current therapies.
Results for the other populations were also intu-
itively consistent. The incremental cost per QALY of
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atomoxetine was lowest in the patient groups with
the fewest alternatives currently available. The in-
cremental cost per QALY was £12,370 and £14,945
for the stimulant-contraindicated (exposed) popula-
tion (population 5) and the stimulant-failed group
(population 2), respectively. In the stimulant-naïve
group (population 1), the incremental cost per QALY
was £15,224 (compared with the IR-MPH algorithm;
Evaluation A) or £13,241 (compared with the
XR-MPH algorithm; Evaluation B). In the stimulant-
averse group (population 3; Evaluation B), the incre-
mental cost per QALY of atomoxetine compared with
the XR-MPH algorithm was £14,169 (Table 5).
Sensitivity Analysis
A comprehensive range of univariate and multivariate
sensitivity analyses were performed for uncertain
model variables and assumptions (the results of which
are available from the authors upon request). In
general, the incremental cost per QALY gained in each
population was insensitive to univariate changes in key
clinical and cost variables. Nevertheless, the sensitivity
analyses show that the utility values of the most popu-
lous health states are important determinants of the
cost-effectiveness of atomoxetine.
Given the importance of the utility values to the
results of the economic model, additional sensitivity
analyses of the utility values were explored. The inten-
tion of these additional sensitivity analyses was to see
how the results of the model are affected when differ-
ences between utility values of corresponding health
states for all treatments are reduced or eliminated.
That is, how will incremental cost-effectiveness ratios
be affected by the systematic reduction in the differ-
ence between atomoxetine utility values and those
of IR-MPH, XR-MPH, IR-DEX, and no treatment
for each health state. This analysis was performed
for stimulant-naive patients (population 1) versus
IR-MPH or XR-MPH (results shown in Fig. 3).
The incremental cost per QALY gained was
between £13,000 and £18,000 per QALY for the base-
case analysis. When differences in the utility values
between corresponding health states of different treat-
ments were reduced to 75% of the value given in the
utility survey, the results were between £17,000 and
£24,000 per QALY. The incremental cost per QALY
reached a range of £42,000 to £62,000 per QALY
when differences in utilities are reduced to 25% of the
original values. Finally, when differences in utilities
are eliminated, the incremental cost per QALY ratio
increases dramatically.
This sensitivity analysis shows that when differ-
ences in utility values between treatment groups are
removed the incremental cost per QALY gained of
atomoxetine rises to unacceptable levels. However, the
modest increase in the cost per QALY when differences
are reduced by up to 75% and the sound methodology
used to derive the utility values [26] serve to minimize
Table 5 Total costs, QALYs and incremental cost-effectiveness estimated in the economic model by treatment group and patient
population
Population
Cost per patient QALYs per patient
Incremental cost
per QALY gained
Atomoxetine
algorithm
Comparator
algorithm Difference
Atomoxetine
algorithm
Comparator
algorithm Incremental
Population 1:
Stimulant-naive patients
(Evaluation A: IR-MPH
comparison)
£534.09 £125.76 £408.34 0.9308 0.9040 0.0268 £15,224
Population 1:
Stimulant-naive patients
(Evaluation B: XR-MPH
comparison)
£599.78 £334.07 £265.71 0.9341 0.9140 0.0201 £13,241
Population 2:
Stimulant-failed patients
£488.26 £39.48 £448.78 0.9268 0.8967 0.0300 £14,945
Population 3:
Stimulant-averse patients
(Evaluation A: IR-MPH
comparison)
£493.05 £119.27 £373.79 0.9263 0.9028 0.0235 £15,878
Population 3:
Stimulant-averse patients
(Evaluation B: XR-MPH
comparison)
£568.96 £312.83 £256.13 0.9301 0.9120 0.0181 £14,169
Population 4:
Stimulant-contraindicated
patients (naive)
£480.94 £0.00 £480.94 0.9217 0.8800 0.0417 £11,523
Population 5:
Stimulant-contraindicated
patients (exposed)
£395.98 £0.00 £395.98 0.9120 0.8800 0.0320 £12,370
IR-MPH, immediate-release methylphenidate; QALY, quality-adjusted life-year; Stimulant-exposed, patients with attention-deﬁcit/hyperactivity disorder (ADHD) who have
previously tried and failed on methylphenidate because of lack of response; Stimulant-naive, ADHD patients who have never been exposed to methylphenidate, dexamphetamine,
or any other stimulant medication; XR-MPH, extended-release methylphenidate; Failure/nonfailure, whether stimulant-exposed patients failed methylphenidate or not.
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the uncertainty surrounding the utility values and thus
maximize the reliability of the results of the base-case
model.
Discussion and Conclusions
With new innovative technologies and pharmaceuti-
cal interventions developing alongside an increasing
demand for improved health care, upward pressure
on health-care costs is inevitable. With this in mind,
payers must decide which technologies and interven-
tions will provide best value-for-money. The quality
of life gains associated with treatments can be quan-
tiﬁed via cost-utility analysis, and such analysis plays
a vital role in informing the decision-making process
that determines which technologies or interventions
should be funded. Cost-utility analysis is considered
the most appropriate approach to the economic
evaluation for the purpose of decision-making
because QALYs are a ﬁnal health outcome and are
not disease-speciﬁc. This allows the quality of life
gains from one intervention to be compared directly
with those from interventions over a broad range of
indications. Cost-utility analysis is particularly impor-
tant in ADHD because of the variable nature of
response and disease experience. Quality of life mea-
sures such as utility valuation are able to capture this
variable nature in a way that traditional ADHD efﬁ-
cacy measures cannot.
This cost-utility analysis estimated that the incre-
mental cost per QALY gained by inclusion of atomox-
etine within the treatment algorithm was between
£11,523 and £15,878, depending on the patient
group and comparator algorithms. The results of
the modeled economic evaluation and associated sen-
sitivity analyses conﬁrmed the utility values to be a
key component in determining the cost-effectiveness
of atomoxetine. Additionally, sensitivity analyses re-
vealed a minimal impact of response rates, adverse
events, and other transition probabilities.
Given that the utility values were a key factor inﬂu-
encing cost-effectiveness, it is important that users of
this information have conﬁdence in the data and do
not consider this to be a weakness of the model. To this
end, it should be noted that the utility values used in
the evaluation were obtained from a utility valuation
study of ADHD health states [26] that involved
parents of children with ADHD living in the United
Kingdom as the respondent population and used stan-
dard gamble methodology. In order to minimize any
uncertainty or bias surrounding the utility values, the
health states descriptors used in the study interviews
were derived using robust methodology based largely
on data from randomized clinical trials and validated
by experts.
The clinical inputs to the economic model were
primarily based on head-to-head randomized clinical
trial evidence. In ﬁrst-line patients, atomoxetine was
found to be less efﬁcacious than stimulant medica-
tions in terms of the number of patients responding
to treatment. Nevertheless, there is evidence that
patients responding to atomoxetine experience a
more stable and longer-lasting response than those
patients responding to stimulant therapies. Hence,
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Figure 3 The incremental cost per QALY gained of atomoxetine under varying utility values used in the model. IR-MPH, immediate-release methylpheni-
date; QALY, quality of life years; XR-MPH, extended-release methylphenidate.
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the nature of response with atomoxetine, which was
reﬂected in the health state descriptors used in the
utility valuation study, is preferred to that of stimu-
lant treatments.
A second advantage of atomoxetine treatment is
that it represents an additional therapeutic option to
patients with ADHD. Thus, it displaces, as opposed to
replaces, current therapeutic options, resulting in an
increase in the expected time on medication and an
increase in the expected time with response (Fig. 4).
This is also true for those patients who may be
contraindicated to stimulant medications, where “no
medication” would be the only alternative option.
As a consequence of these features, the lower rate of
response for patients treated with atomoxetine com-
pared with stimulant therapies is offset by an improved
medication experience with atomoxetine that, in the
context of the economic evaluation, leads to a greater
number of QALYs overall.
It is recognized that there are several limitations to
this study. First, it could be argued that a longer time
frame may have been desirable to account for longer-
term differences in costs and adverse effects of treat-
ment. Nevertheless, any omissions due to the shorter
time frame are likely to be conservative in that they
bias the model generally against the active therapies,
and more speciﬁcally against atomoxetine. For
example, the model does not allow for the pattern of
care of ADHD patients to change according to
response to active therapy. This means the omission of
nondrug costs within the model is assumed to be the
same across all disease health states. Moreover, in an
ideal situation, it would be preferable to have utility
scores estimated from the patient perspective. Never-
theless, the use of parents of ADHD children as patient
proxies is seen to provide the best practical alternative.
An additional limitation is that the utilities were not
collected in a head-to-head clinical trial. Rather the
health states descriptors were derived from placebo-
controlled clinical trial data and expert opinions, and
utility values were subsequently collected through a
standard gamble survey.
In conclusion, the results of this study show atom-
oxetine to be within the bounds of reasonable cost-
effectiveness for the United Kingdom. The results of
this analysis are considered robust, having been based
on the best available clinical evidence, expert opinion,
and a rigorously conducted utility valuation study of
ADHD-related health states. Furthermore, the out-
comes of this model demonstrate that consideration of
response rates alone does not adequately describe the
entire beneﬁt of atomoxetine. The different nature of
response between the treatments is also seen to be an
important consideration for patients and parents, and
the inclusion of a new therapeutic option adds to the
quality of life for those patients who would have
otherwise failed all treatment options.
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Figure 4 Proportion of population with response by cycle in each of the treatment algorithms (stimulant-naïve patients). ATX, atomoxetine; IR-DEX,
immediate-release dexamphetamine sulfate; med, medication; IR-MPH, immediate-release methylphenidate.
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